Navigation Links
Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
Date:2/27/2008

CORAL SPRINGS, Fla., Feb. 27 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) Oral Solution (Carbinoxamine Maleate Oral Solution) 4 mg/5mL. The Company plans to launch its product immediately.

Carbinoxamine Maleate Oral Solution 4mg/5mL is indicated to treat seasonal and perennial allergic rhinitis.

"This approval is another example of our commitment to providing affordable drug products to customers and consistent innovation in the pharmaceutical industry," commented Robert J. Edwards Jr., CEO. "At Boca Pharmacal we pride ourselves on our ability to offer lower volume items that may have been overlooked by some of the larger generic companies. Carbinoxamine Maleate Oral Solution is the first of many approvals we expect in 2008. Having filed multiple ANDA applications coupled with our multinational partnerships we expect 2008 to be a very big year."

Founded in 1998 Coral Springs, FL based Boca Pharmacal manufactures, develops and distributes a wide variety of generic drugs.


'/>"/>
SOURCE Boca Pharmacal, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line
2. Mission Pharmacal Congratulates Exemplary Womens Health Researchers
3. IDC receives patent on dual energy imaging technology
4. Kryptiq Customer Receives HIMSS Nicholas E. Davies Award of Excellence
5. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
6. Healthy Start of Southwest Florida Receives Grant From March of Dimes to Assess Needs of Pregnant Women and Babies
7. Bishop T. D. Jakes Receives The Black Aids Institute 2008 Heroes in the Struggle Award
8. Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA
9. Florida Tissue Services Receives National Accreditation
10. Siemens Receives FDA Approval for the VERSANT 440 Molecular System
11. Global Med Technologies(R), Inc. Receives FDA 510(K) Clearance for ElDorado Donor(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, ... Over the past 20 years SFI has been recognized as the world’s leader in ... clients into the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, ...
(Date:1/19/2017)... ... 2017 , ... Each year, the Southeastern Society of Plastic ... of surgeons from over fifteen different countries come together to share and learn ... to breast reconstruction for breast cancer patients, teaching these surgical techniques which ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting ... global discussion about the benefits of fidgeting to relieve stress and anxiety. No ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating ... untreated. , Certain Dri created this infographic to explain the seven types of ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... industry’s leading journal and most-read publication among specialty pharmacists and pharmacy professionals, ... through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... 2017   Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies to ... reported the Company,s operating results for 2016 and an ... the Company described in its recent 10-K filing with ... accomplishments. The Company,s contract laboratory completed its evaluation of ...
(Date:1/18/2017)... DAVOS , Suiza, 18 de enero de 2017 ... biofarmacéuticas líderes lanzaron Access Accelerated, una iniciativa global para ... comunicables (NCD) y atención en países de renta baja ... NCD han alcanzado un punto de crisis, particularmente en ... casi el 80 por ciento de las muertes relacionadas ...
Breaking Medicine Technology: